Vyne Therapeutics Inc (VYNE) USD0.0001
Vyne Therapeutics Inc. is a specialty pharmaceutical company. The Company is focused on the developing proprietary therapies in dermatology. The Company's products include AMZEEQ minocycline, is used for the treatment of inflammatory lesions of moderate-to-severe acne vulgaris in adults and patients nine years of age and older, and ZILXI minocycline, is used for the treatment of inflammatory lesions of rosacea in adults. Its product pipeline includes FCD105, is a proprietary topical combination foam formulation of minocycline and adapalene for the treatment of moderate-to-severe acne vulgaris. In addition, it is also developing program for FMX114, which is a combination topical gel for the potential treatment of mild-to-moderate atopic dermatitis. The Company uses its proprietary Molecule Stabilizing Technology (MST) platform to develop FCD105.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.